Recently Closed Protocols

Updated  7/27/06

Click here for:    Current Treatment Protocols

Click here for:    Current Cancer Control Protocols

Bladder

SWOG 4B-95-1     Protocol     MVAC in Organ-Confined Bladder Cancer Based on p53 Status

Brain

SWOG S0001        Protocol   A Phase III Study of Radiation Therapy and 0⁶-Benzylguanine Plus BCNU vs. Radiation Therapy and BCNU Alone for Newly Diagnosed Glioblastoma

Breast

NSABP B-30        Protocol   A Three-Arm Randomized Trial To Compare Adjuvant Adriamycin And Cyclophosphamide Followed By Taxotere (AC → T); Adriamycin And Taxotere (AT); And Adriamycin, Taxotere, And Cyclophosphamide (ATC) In Breast Cancer Patients With Positive Axillary Lymph Nodes

NSABP B-33        Protocol   A Randomized, Placebo-Controlled, double-Blind Trial Evaluating the Effect of Exemestane in Clinical Stage T1-3, N0-1, M0 Postmenopausal Breast Cancer Patients Completing at Least Five Years of Tamoxifen Therapy

NSABP B-34        Protocol   A Clinical Trial Comparing Adjuvant Clodronate Therapy vs. Placebo in Early-Stage Breast Cancer Patients Receiving Systemic Chemotherapy and/or Hormonal Therapy or No Therapy

NSABP B-35     Protocol   A Clinical Trial Comparing Anastrozole with Tamoxifen in Postmenopausal Patients with Ductal Carcinoma in Situ (DCIS) Undergoing Lumpectomy with Radiation Therapy 

JMA.17           Protocol   A Phase III Randomized Double Blind Study of Letrozole Versus Placebo in Women With Primary Breast Cancer Completing Five or More Years of Adjuvant Tamoxifen

SWOG S0029       Protocol    Single Agent Docetaxel For Metastatic Breast Cancer in Patients Ages 70 Years and Older (And In A Cohort of Patients Younger Than 60 Years)

RTOG 98-04    Protocol   Phase III Trial of Tamoxifen Alone vs. Tamoxifen Plus XRT for Good Risk Duct Carcinoma In-Situ (DCIS) of the Female Breast

Colorectal

CTSU E1899    Protocol  A Phase III Randomized Trial for Evaluating Second Line Hormonal Therapy (Ketoconazole/Hydrocortisone) vs. Docetaxel/Estramustine Combination Chemotherapy on Progression-Free Survival in Asymptomatic Patients with a Rising PSA after Hormonal Therapy for Prostate Cancer

CTSU E3201   Protocol   Intergroup Randomized Phase III Study of Postoperative Irinotecan, 5-Fluorouracil, and Leucovorin vs. Oxaliplatin, 5-Fluorouracil, and Leucovorin vs. 5-Fluorouracil and Leucovorin for Patients with Stage II or III Rectal Cancer Receiving Either Preoperative Radiation and 5-Fluorouracil or Postoperative Radiation and 5-Fluorouracil

RTOG 98-11   Protocol   A Phase III Randomized Study of 5-FU, Mitomycin-C and Radiotherapy vs. 5-FU, Cisplatin, and Radiotherapy in Carcinoma of the Anal Canal

Gallbladder

SWOG S0202    Protocol   A Phase II Trial of Gemcitabine and Capecitabine in Patients with Unresectable or Metastatic Gallbladder or Cholangiocarcinoma

Gynecologic

SWOG S0009    Protocol   Phase II Evaluation of Neoadjuvant Chemotherapy, Interval Debulking Followed By Intraperitoneal Chemotherapy in Women with Stage III and IV Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Head & Neck

SWOG S0216   Protocol   Docetaxel (NSC-628503), Cisplatin (NSC-119875), and 5-Fluorouracil (NSC-19893) Induction Chemotherapy Followed by Accelerated Fractionation/Concomitant Boost Radiation and Concurrent Single Agent Cisplatin (NSC-119875), in Patients with Advanced Squamous Cell Head and Neck Cancer

Leukemia

SWOG C9710   Protocol   Phase III Randomized Study of Concurrent Tretinoin and Chemotherapy With Or Without a Single Course of Arsenic Trioxide as Initial Consolidation Therapy Followed by Intermittent Tretinoin Maintenance Therapy Versus Observation For Patients With Untreated Acute Promyelocytic Leukemia

Lung

SWOG S0222      Protocol

A Phase II Study of Tirapazamine/Cisplatin/Etoposide and Concurrent Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer

S0339        Protocol   A Phase II Trial of Gemcitabine, Carboplatin and PS-341 (NSC-681239) in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC).

S0342    Protocol   Phase II Selection Design Trial of Concurrent Chemotherapy + Cetuximab vs. Chemotherapy Followed by Cetuximab in Advanced Non-Small Cell Lung Cancer (NSCLC)

S0341    Protocol   Phase II Trial of OSI-774 (NSC-718781) in Patients with Advanced Non-Small Cell Lung Cancer and a Performance Status of 2

Lymphoma

SWOG S0349     Protocol    Standard Dose Cyclophosphamide, Doxorubicin, Vincristine, Prednisone and Rituximab, or Rituximab and G3139 Phosphorothioate (Anti-BCL-2 Antisense) Therapy for Young Patients with Advanced Stage Diffuse Large B-Cell NHL of Low and Low-Intermediate IPI Risk

E2496   Protocol  Randomized Phase III Trial of ABVD Versus Stanford V + Radiation Therapy in Locally Extensive and Advanced Stage Hodgkin's Disease with 0-2 Risk Factors

Myeloma

SWOG S0204       Protocol   A Phase II Trial of Thalidomide/Dexamethasone Induction Followed by Tandem Melphalan Transplant and Prednisone/Thalidomide Maintenance in Newly Diagnosed Multiple Myeloma Patients

CTSU E4A03      Protocol   A Randomized Phase III Study of CC-5013 Plus Dexamethasone versus CC-5013 Plus Low-Dose Dexamethasone in Multiple Myeloma with Thalidomide plus Dexamethasone Salvage Therapy for Non-Responders

Ovarian

GOG 0182        Protocol   A Phase III Randomized Trial of Paclitaxel and Carboplatin Versus Triplet or Sequential Doublet Combinations in Patients with Epithelial Ovarian or Primary Peritoneal Carcinoma

Pancreas

CTSU E6201    Protocol   A Phase III Randomized Study of Gemcitabine (fixed-dose rate infusion) and Oxaliplatin (NSC #266046) vs. Gemcitabine (fixed-dose rate infusion) vs. Gemcitabine (30-minute infusion) in Pancreatic Carcinoma

SWOG 0420    Protocol  Phase II Evaluation of BAY 43-9006 (NSC-724772) in Patients with Recurrent or Metastatic Head and Neck Cancer

SWOG S0205    Protocol    Phase III Randomized Open-Label Study Comparing Gemcitabine Plus Cetuximab vs. Gemcitabine as First-Line Therapy of Patients with Advanced Pancreas Cancer

NCCTG N034A    Protocol   Phase II Study of Bevacizumab, Gemcitabine, Oxaliplatin in Patients with Metastatic Pancreatic Cancer

CALGB 80303        Protocol    A Randomized Phase III Trial of Gemcitabine plus Bevacizumab vs. Gemcitabine plus Placebo in Patients with Advanced Pancreatic Cancer

Prostate

S0032   Protocol    Phase II Evaluation of Early Oral Estramustine, Oral Etoposide and Intravenous Paclitaxel in Combination with Hormone Therapy in Patients with High Risk Metastatic Adenocarcinoma of the Prostate

JPR.7        Protocol     A Phase III Randomized Trial Comparing Intermittent Versus Continuous Androgen Suppression for Patients with Prostate-Specific-Antigen Progression in the Clinical Absence of Distant Metastases Following Radiotherapy for Prostate Cancer

 Renal

CTSU CALGB 90206    Protocol   A Randomized Phase III Trial of Interferon Alfa-2B or Interferon Alfa-2B Plus Bevacizumab in Patients with Advanced Renal Carcinoma

SWOG S0312      Protocol   A Phase II Study of IV Gemcitabine and Oral Capecitabine in Patients with Advanced Renal Cell Cancer

Stomach

SWOG S0413    Protocol     Phase II Study of GW572016 as First Line Therapy in Patients with Advanced or Metastatic Gastric Cancer

Cancer Control

Fatigue

NCCTG N03CA     Protocol    The Use of American Ginseng to Improve Cancer-Related Fatigue:  A Randomized, Double-Blind, Dose Finding, Placebo-Controlled Study

Diarrhea

NCCTG N00CA     Protocol   A Phase III Double-Blind Study of Depot Octreotide vs. Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy

Osteoporosis

NCCTG  N02C1     Protocol   A Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Risendronate (Actonel) for Prevention of Bone Loss in Premenopausal Women Undergoing Chemotherapy for Primary Breast Carcinoma

NCCTG N03CC    Protocol    A Randomized, Controlled, Open-label Trial of Empiric Prophylactic vs Delayed Use of Zoledronic Acid for Prevention of Bone Loss in Postmenopausal Women with Breast Cancer Initiating Therapy with Letrozole after Tamoxifen